CardioNerds @AHA23: ARIES HM3: Avoidance of Aspirin with LVAD Devices

Published: 27 Nov 2023

  • Views:

    Views Icon 506
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156). 

ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens. One treatment group received a Vitamin K antagonist, whereas another group received a vitamin K antagonist with placebo. 

The non-inferiority endpoint for this study will be met if the placebo arm is non-inferior to the aspirin arm in the composite of survival free of any non-surgical major hemocompatibility-related adverse event at one-year post-implant. 

Results showed that excluding aspirin from an antithrombotic regime that includes a VKA in advanced heart failure patients with an LVAD was non-inferior to an aspirin-containing regimen, and was associated with decreased bleeding events without increased risk of thromboembolic events. There was also a 47% decrease in days spent in the hospital, and a 41% reduction in the cost of care for bleeding events. Researchers estimate that for each 100 patients implanted with the study LVAD, aspirin avoidance therapy prevented 14.5 major bleeding events in the first year.

Recorded on-site at AHA 2023, Philadelphia.

Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.


You must be to comment. If you are not registered, you can register here.